LABORATOIRES EUROMEDIS (ALEMG.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALEMG - FR0000075343 - Common Stock
3.91 EUR
0 (0%)
Overall ALEMG gets a fundamental rating of 3 out of 10. We evaluated ALEMG against 65 industry peers in the Health Care Equipment & Supplies industry. ALEMG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALEMG has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ALEMG has reported negative net income.
In multiple years ALEMG reported negative net income over the last 5 years.
In multiple years ALEMG reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of ALEMG (27.66%) is better than 98.46% of its industry peers.
ALEMG's Return On Equity of 57.02% is amongst the best of the industry. ALEMG outperforms 98.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.66% | ||
| ROE | 57.02% | ||
| ROIC | N/A |
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALEMG has a better Profit Margin (24.05%) than 90.77% of its industry peers.
The Gross Margin of ALEMG (31.89%) is worse than 81.54% of its industry peers.
ALEMG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 24.05% | ||
| GM | 31.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
Compared to 1 year ago, ALEMG has about the same amount of shares outstanding.
The number of shares outstanding for ALEMG has been reduced compared to 5 years ago.
The debt/assets ratio for ALEMG has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.68, we must say that ALEMG is in the distress zone and has some risk of bankruptcy.
ALEMG has a worse Altman-Z score (1.68) than 63.08% of its industry peers.
A Debt/Equity ratio of 0.41 indicates that ALEMG is not too dependend on debt financing.
ALEMG has a Debt to Equity ratio of 0.41. This is comparable to the rest of the industry: ALEMG outperforms 49.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.68 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 3.47 indicates that ALEMG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.47, ALEMG belongs to the top of the industry, outperforming 87.69% of the companies in the same industry.
ALEMG has a Quick Ratio of 2.57. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.
ALEMG has a better Quick ratio (2.57) than 87.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.47 | ||
| Quick Ratio | 2.57 |
3. Growth
3.1 Past
The earnings per share for ALEMG have decreased strongly by -178.48% in the last year.
ALEMG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -38.33%.
ALEMG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -14.02% yearly.
EPS 1Y (TTM)-178.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.68%
Revenue 1Y (TTM)-38.33%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%-47.27%
3.2 Future
ALEMG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.07% yearly.
ALEMG is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.80% yearly.
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ALEMG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 8.76, the valuation of ALEMG can be described as very reasonable.
93.85% of the companies in the same industry are more expensive than ALEMG, based on the Price/Forward Earnings ratio.
ALEMG's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.76 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALEMG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALEMG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALEMG (1/6/2026, 7:00:00 PM)
3.91
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners1.67%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.22M
Revenue(TTM)36.22M
Net Income(TTM)12.58M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.76 | ||
| P/S | 0.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.51 | ||
| P/tB | 0.51 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.15
EYN/A
EPS(NY)0.45
Fwd EY11.42%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS18.22
BVpS7.69
TBVpS7.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.66% | ||
| ROE | 57.02% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 24.05% | ||
| GM | 31.89% | ||
| FCFM | N/A |
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
F-ScoreN/A
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.47 | ||
| Quick Ratio | 2.57 | ||
| Altman-Z | 1.68 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-178.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.68%
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-38.33%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%-47.27%
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
LABORATOIRES EUROMEDIS / ALEMG.PA FAQ
What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ALEMG.PA.
Can you provide the valuation status for LABORATOIRES EUROMEDIS?
ChartMill assigns a valuation rating of 3 / 10 to LABORATOIRES EUROMEDIS (ALEMG.PA). This can be considered as Overvalued.
What is the profitability of ALEMG stock?
LABORATOIRES EUROMEDIS (ALEMG.PA) has a profitability rating of 3 / 10.
How financially healthy is LABORATOIRES EUROMEDIS?
The financial health rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 5 / 10.
How sustainable is the dividend of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?
The dividend rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 0 / 10 and the dividend payout ratio is 0%.